Abstract
Vasopressin receptor antagonists (vaptans) are a new class of drugs to treat congestive heart failure. Since there are three subtypes of the receptor located in different tissues, it is important to devise tailor-made vaptans to target the appropriate receptor subtype. The binding of three vaptans, OPC21268, mozavaptan and tolvapatan was measured to the human V1-vascular vasopressin receptor (hV1R). Whereas arginine vasopressin (AVP) binds to hV1R and hV2R with equal affinity, vaptans interact differently with the receptor subtypes. The interaction of the three vaptans to the hV1R was probed by binding experiments to point mutants of residues postulated to line the binding pocket. The measurements suggest that the binding pocket on the hV1R is too small for tight binding of tolvaptan. The somewhat smaller mozavaptan is a slightly better binder to the hV1R. The data suggest ways to increase the affinity of tolvaptan to the hV1R by chemical modification.
Keywords: Antagonist, GPCR, Receptor, Mozavaptan, Tolvaptan, Vaptan, Vasopressin, arginine vasopressin (AVP), hV1R, vasodilation, hyponatremia, hypervolemia, V2R, adenylyl cyclase
Letters in Drug Design & Discovery
Title: Specificity of Three Vasopressin Receptor Antagonists
Volume: 8 Issue: 6
Author(s): Jeremy T. Saks, Barbara Truitt and Menachem Shoham
Affiliation:
Keywords: Antagonist, GPCR, Receptor, Mozavaptan, Tolvaptan, Vaptan, Vasopressin, arginine vasopressin (AVP), hV1R, vasodilation, hyponatremia, hypervolemia, V2R, adenylyl cyclase
Abstract: Vasopressin receptor antagonists (vaptans) are a new class of drugs to treat congestive heart failure. Since there are three subtypes of the receptor located in different tissues, it is important to devise tailor-made vaptans to target the appropriate receptor subtype. The binding of three vaptans, OPC21268, mozavaptan and tolvapatan was measured to the human V1-vascular vasopressin receptor (hV1R). Whereas arginine vasopressin (AVP) binds to hV1R and hV2R with equal affinity, vaptans interact differently with the receptor subtypes. The interaction of the three vaptans to the hV1R was probed by binding experiments to point mutants of residues postulated to line the binding pocket. The measurements suggest that the binding pocket on the hV1R is too small for tight binding of tolvaptan. The somewhat smaller mozavaptan is a slightly better binder to the hV1R. The data suggest ways to increase the affinity of tolvaptan to the hV1R by chemical modification.
Export Options
About this article
Cite this article as:
T. Saks Jeremy, Truitt Barbara and Shoham Menachem, Specificity of Three Vasopressin Receptor Antagonists, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906794
DOI https://dx.doi.org/10.2174/157018011795906794 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiotensin-(1-7), Angiotensin-Converting Enzyme 2 and Mas Receptor in Rat Polycystic Ovaries
Protein & Peptide Letters Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review on the Neuroprotective Effect of Berberine against Chemotherapy- induced Cognitive Impairment
Current Drug Targets MicroRNA Regulation and Role in Stem Cell Maintenance, Cardiac Differentiation and Hypertrophy
Current Molecular Medicine Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry Use of N-acetyl-cysteine to Prevent Nephrotoxicity Associated with Iodinated Contrast Agents
Current Drug Therapy Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Use of Diuretics in Women for Management of Hypertension
Current Hypertension Reviews Cell Based Approaches for Myocardial Regeneration and Artificial Myocardium
Current Stem Cell Research & Therapy Why Not All Hypertensive Patients Are Tachycardic at Rest?
Current Pharmaceutical Design Treatment of Acute Hypercalcemia
Medicinal Chemistry Nitric Oxide Pathway as New Drug Targets for Refractory Hypertension
Current Pharmaceutical Design Hematocrit-lowering Effect Following Inactivation of Renin-Angiotensin System with Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
Current Topics in Medicinal Chemistry Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science Retinoic Acid Metabolism and Mechanism of Action: A Review
Current Drug Metabolism Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry Editorial from Editor-in-Chief: Lung Dialysis: Are We There Yet?
Current Respiratory Medicine Reviews Unconventional Players on the Striated Muscle Field: microRNAs, Signaling Pathways and Epigenetic Regulators
Current Stem Cell Research & Therapy Aesthetic Cardiology: Adipose-Derived Stem Cells for Myocardial Repair
Current Stem Cell Research & Therapy